Skip to main content
  • AltaValve TMVR Device Shows Clinical, Procedural Benefits at 6 Months: EFS

    In patients with symptomatic, severe mitral regurgitation (MR) undergoing transcatheter mitral valve replacement (TMVR), the AltaValve system shows sustained clinical benefits, reduction of MR and potential treatment strategies for several mitral valve (MV) anatomies, according to the updated results from the AltaValve early feasibility study (EFS). 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details